儿童脑桥弥漫性中线胶质瘤放疗后MR成像特征与分子及突变分析的相关性
本研究基于多中心临床试验,纳入41例儿童脑桥弥漫性中线胶质瘤患者,分析放疗后2个月和4个月MR成像特征与组蛋白突变状态及总生存期的关联。结果显示,除放疗后4个月强化体积外,所有成像特征从基线到放疗后2个月和4个月均有统计学显著变化;在H3突变肿瘤中,H3C2/3组在放疗后2个月多个nADC直方图指标显著高于H3-3A组;放疗后MR成像特征与潜在突变状态存在差异相关。
要点
- 放疗后2个月和4个月,除强化体积外,T2/FLAIR体积及nADC直方图指标较基线有显著变化。
- H3C2/3突变组放疗后2个月的平均、中位和众数nADC_FLAIR及众数nADC-强化显著高于H3-3A组。
- 上述nADC直方图指标差异在放疗后4个月未达统计学显著。
核心结论
- 放疗后MR成像特征与儿童脑桥弥漫性中线胶质瘤的潜在突变状态存在差异相关。
研究设计与样本
- 机构审查委员会批准的多中心临床试验「分子决定治疗弥漫内生型脑桥胶质瘤」的一部分,41例符合条件,35例明确突变状态,所有患者治疗前活检并接受标准放疗联合辅助贝伐珠单抗,根据活检标本甲基化状态和表皮生长因子受体表达分层,采用Wilcoxon秩和检验比较突变亚组。
关键影像表现/征象
- 放疗后2个月和4个月T2/FLAIR体积及nADC直方图指标(均值、中位数、众数、偏度、峰度)较基线有统计学显著变化(P < .05),但放疗后4个月强化体积除外。
- 在H3突变肿瘤患者(n = 27)中,H3C2/3组放疗后2个月的平均nADC_FLAIR(P = .05)、众数nADC_FLAIR(P = .003)、中位nADC_FLAIR(P = .02)和众数nADC-强化(P = .04)显著高于H3-3A组。
- 上述nADC直方图指标在放疗后4个月未达统计学显著差异。
- H3突变型与野生型肿瘤放疗后ADC直方图指标无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: We aimed to describe the postradiation imaging features in children with pontine pediatric diffuse midline glioma, and to identify associations between these changes and histone mutational status, as well as overall survival.
MATERIALS AND METHODS: Patients were recruited as part of an institutional review board-approved, multicenter clinical trial: Molecularly Determined Treatment of Diffuse Intrinsic Pontine Glioma. Subjects had baseline MR imaging that showed classic imaging criteria of pontine diffuse midline glioma and postradiation imaging at regular intervals. All patients underwent biopsy before therapy initiation and received standard radiation therapy with adjuvant bevacizumab. Patients were subsequently stratified based on methylation status and epidermal growth factor receptor expression in the biopsy specimen. Imaging analyses included postradiation T2/FLAIR and enhancing tumor volumes, as well as normalized ADC (nADC) histogram metrics (mean, median, mode, skewness, and kurtosis) at 2 and 4 months postradiation. The mutation subgroups were compared by using a Wilcoxon rank-sum test.
RESULTS: Forty-one patients met eligibility criteria, and mutational status was identified in 35. The median age was 6 years (range: 1.2-17). Seventeen of 35 (49%) had H3-3A histone mutations, 10 of 35 (29%) had H3C2/3, and 8 of 35 (22%) were wild-type (WT). Except for enhancing volume at postradiation time point 2 (4 months postradiation; RT2), all imaging features had a statistically significant change (P < .05) from baseline to time point 1 (2 months postradiation; RT1) and RT2. Within the cohort of patients that had H3-mutant tumors (n = 27), patients with H3C2/3 had statistically significantly higher mean nADC_FLAIR (P = .05), mode nADC_FLAIR (P = .003), median nADC_FLAIR (P = .02), and mode nADC-enhancement (P = .04) than patients with H3-3A at RT1. These nADC histogram metrics were not statistically significantly different at RT2. Moreover, we found no statistically significant difference in ADC histogram metrics postradiation, when we compared H3-mutant versus WT tumors.
CONCLUSIONS: Postradiation MR imaging features are differentially correlated with the underlying mutational status of pediatric pontine diffuse midline glioma.
引用
- Rameh V, Ziaei A, Vajapeyam S, et al. Postradiation MR Imaging Features in Molecular and Mutational Analyses in Pontine Pediatric Diffuse Midline Gliomas. AJNR Am J Neuroradiol. 2025. PMID: 40280708. doi:10.3174/ajnr.A8817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。